港股详情

本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

派格生物医药-B

60.700

-2.550-4.03%

成交量：83.76万

成交额：5,355.15万

市值：234.30亿

市盈率：-71.88

高：72.750

开：72.700

低：55.050

收：63.250

52周最高：72.750

52周最低：8.680

股本：3.86亿

香港流通股本：2.79亿

量比：4.00

换手率：0.30%

股息：- -

股息率：- -

每股收益(LYR):-0.845

净资产收益率：-224.15%

总资产收益率：-61.30%

市净率：83.95

市盈率(LYR):-71.88

市销率: -5529.03

数据加载中...

总览公司新闻资讯公告

近期国内融资|派格生物、先通医药、和美药业赴港上市

派格生物医药-B06月02日主力净流出20.6万元散户资金买入

GLP-1新锐IPO，核心管线即将上市

异动解读 | 派格生物医药-B盘中暴跌5.02%，延续IPO破发颓势

异动解读 | 港股新股派格生物医药-B盘中大跌5.02%，上市第二日继续下挫

异动解读 | GLP-1赛道新星派格生物医药-B盘中大涨5.36%，投资者看好其商业化前景

21健讯Daily｜小儿感冒宁颗粒和蒲公英颗粒转为非处方药；派格生物港交所上市；漱玉平民股东拟减持

核药龙头与GLP-1新锐齐赴港，科五标准重启，Biotech IPO春天来了？

产业投资丨中新资本已投企业派格生物（2565.HK）成功登陆港交所

今天，杭州派格生物IPO了

市值超48亿！联想云锋投的“减肥药”IPO了

港股异动丨派格生物医药-B上市首日破发，一度大跌26%

老虎资讯综合

中银国际助力派格生物成功在香港联交所上市

港交所又迎来一家药企上市

《股市简讯》中国“减肥药概念股”派格生物医药香港首日挂牌盘初插水近三成

中泰国际助力减重疗法概念股－“派格生物医药”（2565.HK）成功上市！

中泰金融国际

异动解读 | 派格生物医药-B上市首日暴跌15%，开盘即破发

异动解读 | 派格生物医药-B上市首日遭遇破发，盘中大跌15%

9轮融资、众多头部机构加持，减肥药明星企业今日IPO

新股定价 | 派格生物医药每股定价15.6港元，公开发售获743.78倍认购，一手中签率8%

老虎资讯综合

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/stock/02565/news?page=4"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"02565","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02565\",,,,,undefined,":{"symbol":"02565","market":"HK","secType":"STK","nameCN":"派格生物医药-B","latestPrice":60.7,"timestamp":1763366895008,"preClose":63.25,"halted":0,"volume":837550,"delay":0,"floatShares":279164339,"shares":386000000,"eps":-0.8445119096732067,"marketStatus":"未开盘","change":-2.55,"latestTime":"11-17 16:08:15","open":72.7,"high":72.75,"low":55.05,"amount":53551500,"amplitude":0.279842,"askPrice":60.7,"askSize":6500,"bidPrice":60.05,"bidSize":1000,"shortable":3,"etf":0,"ttmEps":-0.6570254692329219,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1763429400000},"marketStatusCode":0,"adr":0,"listingDate":1748275200000,"exchange":"SEHK","adjPreClose":63.25,"openAndCloseTimeList":[[1763343000000,1763352000000],[1763355600000,1763366400000]],"volumeRatio":3.995945,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02565\",,,,,undefined,":{"symbol":"02565","floatShares":279164339,"roa":"-61.30%","roe":"-224.15%","lyrEps":-0.844512,"volumeRatio":3.995945,"shares":386000000,"dividePrice":0,"high":72.75,"amplitude":0.279842,"preClose":63.25,"low":55.05,"week52Low":8.68,"pbRate":"83.95","psRate":"-5529.03","week52High":72.75,"institutionHeld":0,"latestPrice":60.7,"committee":-0.733333,"eps":-0.8445119096732067,"divideRate":0,"volume":837550,"delay":0,"ttmEps":-0.6570254692329219,"open":72.7,"prevYearClose":15.6,"prevWeekClose":63.25,"prevMonthClose":60.1,"prevQuarterClose":54.2,"fiveDayClose":53.4,"twentyDayClose":52.05,"sixtyDayClose":30.76},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/02565\",params:#limit:5,,,undefined,":[{"date":"2025-08-26","symbol":"02565","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1756171800000,"name":null,"time":"","dateTimestamp":1756137600000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"02565\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"02565\",market:\"HK\",delay:false,,,undefined,":{"strongBuy":0,"buy":0,"hold":0,"sell":0,"strongSell":1,"meanLabel":"STRONG SELL","meanPercent":1,"analysts":1,"updateTime":1755446400000},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/02565\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"02565","date":"2025-11-14","current":-92.37825,"percent":0,"low":-72.819022,"twenty":-61.035505,"median":-39.959751,"eighty":-12.906561,"high":-11.114373,"avg":-37.222505,"sd":22.07937,"marketCap":17657144441},"quantilePoints":[{"date":"2025-05-30","current":-12.743079,"twenty":-15.470266,"median":-13.542645,"eighty":-13.135794,"marketCap":3936746426},{"date":"2025-06-06","current":-11.987888,"twenty":-13.726785,"median":-12.740515,"eighty":-12.114178,"marketCap":3712892217},{"date":"2025-06-13","current":-11.23576,"twenty":-13.295707,"median":-12.114337,"eighty":-11.528404,"marketCap":3481318898},{"date":"2025-06-20","current":-11.30775,"twenty":-12.841258,"median":-11.963331,"eighty":-11.337793,"marketCap":3496757119},{"date":"2025-06-27","current":-12.421214,"twenty":-12.738977,"median":-11.541778,"eighty":-11.292079,"marketCap":3851836209},{"date":"2025-07-04","current":-13.963875,"twenty":-12.971799,"median":-11.987888,"eighty":-11.299391,"marketCap":4330421069},{"date":"2025-07-11","current":-13.604213,"twenty":-13.050401,"median":-12.199189,"eighty":-11.305737,"marketCap":4214634409},{"date":"2025-07-18","current":-16.956264,"twenty":-13.748078,"median":-12.438987,"eighty":-11.330282,"marketCap":5248995235},{"date":"2025-07-25","current":-19.006677,"twenty":-15.472199,"median":-12.742066,"eighty":-11.352726,"marketCap":5905119639},{"date":"2025-08-01","current":-19.199848,"twenty":-18.276271,"median":-12.906561,"eighty":-11.424474,"marketCap":5928276971},{"date":"2025-08-08","current":-20.51103,"twenty":-19.019895,"median":-13.05938,"eighty":-11.472546,"marketCap":6348968501},{"date":"2025-08-15","current":-39.959751,"twenty":-19.179784,"median":-13.542645,"eighty":-11.515029,"marketCap":12350577024},{"date":"2025-08-22","current":-41.864246,"twenty":-19.284777,"median":-13.964282,"eighty":-11.779976,"marketCap":12898633879},{"date":"2025-08-29","current":-41.44792,"twenty":-21.432837,"median":-14.946806,"eighty":-11.968242,"marketCap":10033166343},{"date":"2025-09-05","current":-50.678037,"twenty":-39.039264,"median":-17.018603,"eighty":-12.06328,"marketCap":12255314482},{"date":"2025-09-12","current":-58.538001,"twenty":-40.749762,"median":-18.438762,"eighty":-12.114019,"marketCap":14181548421},{"date":"2025-09-19","current":-57.311117,"twenty":-43.720929,"median":-18.952908,"eighty":-12.216159,"marketCap":13874467648},{"date":"2025-09-26","current":-63.587749,"twenty":-49.33228,"median":-19.070122,"eighty":-12.366345,"marketCap":15354038645},{"date":"2025-10-03","current":-60.149194,"twenty":-54.575673,"median":-19.16943,"eighty":-12.428323,"marketCap":14558420278},{"date":"2025-10-10","current":-60.121463,"twenty":-57.957283,"median":-19.199848,"eighty":-12.49878,"marketCap":14530503844},{"date":"2025-10-17","current":-60.168303,"twenty":-59.756564,"median":-19.2984,"eighty":-12.738571,"marketCap":14530503844},{"date":"2025-10-24","current":-61.301982,"twenty":-60.143648,"median":-20.51103,"eighty":-12.741458,"marketCap":14809668183},{"date":"2025-10-31","current":-69.345185,"twenty":-60.159469,"median":-22.018639,"eighty":-12.743079,"marketCap":16777776773},{"date":"2025-11-07","current":-59.401661,"twenty":-60.392128,"median":-34.33922,"eighty":-12.780248,"marketCap":14363005241},{"date":"2025-11-14","current":-72.819022,"twenty":-61.035505,"median":-39.959751,"eighty":-12.906561,"marketCap":17657144441}],"updateTime":1763398128357},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"02565\",pageSize:20,pageCount:4,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2540173773","title":"近期国内融资|派格生物、先通医药、和美药业赴港上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2540173773","media":"药菓","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540173773?lang=zh_cn&edition=fundamental","pubTime":"2025-06-03 18:00","pubTimestamp":1748944826,"startTime":"0","endTime":"0","summary":"主要应用于在神经、心血管、肿瘤三大疾病领域，先通医药已实现全面布局，并拥有多款精准诊断和靶向治疗放射性药物研发管线。舜景医药创立于2018年，是一家创新驱动型生物医药技术公司，致力于原创性抗体药物的发现、开发以及商业化。和美药业已开发七个小分子候选药物，其中四种候选药物处于II期、 III期临床。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250603180612a6f872d5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":"a6ebb226f01ab1197d003ac8f442408e","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250603180612a6f872d5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","BK1515","BK1574","02565","09939"],"gpt_icon":1},{"id":"2540766489","title":"派格生物医药-B06月02日主力净流出20.6万元 散户资金买入","url":"https://stock-news.laohu8.com/highlight/detail?id=2540766489","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540766489?lang=zh_cn&edition=fundamental","pubTime":"2025-06-02 16:15","pubTimestamp":1748852155,"startTime":"0","endTime":"0","summary":"06月02日, 派格生物医药-B股价跌5.10%，报收9.68元，成交金额835.9万元，换手率0.31%，振幅6.86%，量比0.00。派格生物医药-B今日主力资金净流出20.6万元，上一交易日主力净流出0万元。该股近5个交易日下跌37.95%，主力资金累计净流出226.1万元；近20日主力资金累计净流出226.1万元，其中净流出天数为2日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250602162920a6f6d255&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250602162920a6f6d255&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02565"],"gpt_icon":0},{"id":"2538012420","title":"GLP-1新锐IPO，核心管线即将上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2538012420","media":"药时代","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538012420?lang=zh_cn&edition=fundamental","pubTime":"2025-05-28 17:32","pubTimestamp":1748424761,"startTime":"0","endTime":"0","summary":"正文共2700字 3图预计阅读时间8分钟2025年5月27日，GLP-1新锐派格生物正式登陆港交所，中金公司担任独家保荐人。产品管线主要围绕GLP-1，致力于为患者提供安全、有效、便捷且具有多重临床获益的创新疗法。当前，全球减重药物市场正经历结构性变革，以GLP-1受体激动剂为代表的创新疗法成为推动行业发展的核心力量。作为GLP-1领域的新兴力量，派格生物正蓄势待发，准备在这红海市场中占据一席之地。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250528191102a48fc049&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250528191102a48fc049&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02565"],"gpt_icon":0},{"id":"1191654599","title":"异动解读 | 派格生物医药-B盘中暴跌5.02%，延续IPO破发颓势","url":"https://stock-news.laohu8.com/highlight/detail?id=1191654599","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1191654599?lang=zh_cn&edition=fundamental","pubTime":"2025-05-28 09:56","pubTimestamp":1748397403,"startTime":"0","endTime":"0","summary":"派格生物医药-B今日盘中大跌5.02%，延续了其港股上市首日的颓势。该公司昨日在港交所正式挂牌上市，但首日股价就出现大幅下跌。派格生物医药成立于2008年，专注于自主研究及开发慢性病创新疗法，重点关注内分泌代谢领域。目前，公司有6款候选产品，但尚未有商业化产品。其中，进展最快的是一款GLP-1激动剂PB-119，其针对糖尿病的单药和联合疗法已提交上市注册申请。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["02565"],"gpt_icon":0},{"id":"1188425710","title":"异动解读 | 港股新股派格生物医药-B盘中大跌5.02%，上市第二日继续下挫","url":"https://stock-news.laohu8.com/highlight/detail?id=1188425710","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1188425710?lang=zh_cn&edition=fundamental","pubTime":"2025-05-28 09:56","pubTimestamp":1748397401,"startTime":"0","endTime":"0","summary":"5月28日上午，港股新上市公司派格生物医药-B盘中大跌5.02%，延续了上市首日的跌势，引发投资者关注。派格生物医药于5月27日在港交所正式挂牌上市，发行价为15.6港元。然而，上市首日即遭遇破发，收盘价为11.66港元，大跌25.9%。派格生物医药成立于2008年，专注于自主研究及开发慢性病创新疗法，重点关注内分泌代谢领域。分析人士认为，派格生物医药股价持续下跌，可能与公司尚未盈利且产品未实现商业化有关。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["02565"],"gpt_icon":0},{"id":"1113728130","title":"异动解读 | GLP-1赛道新星派格生物医药-B盘中大涨5.36%，投资者看好其商业化前景","url":"https://stock-news.laohu8.com/highlight/detail?id=1113728130","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1113728130?lang=zh_cn&edition=fundamental","pubTime":"2025-05-28 09:35","pubTimestamp":1748396118,"startTime":"0","endTime":"0","summary":"港股上市第二日，派格生物医药-B今日盘中大涨5.36%，引发市场广泛关注。这家专注于自主研发慢性病创新疗法的生物技术公司，正吸引着投资者的目光。派格生物医药于5月27日在港交所成功上市，发行价为15.6港元/股。其核心产品PB-119是一款每周一次的长效GLP-1激动剂，已完成III期试验并在2023年提交国内上市申请，预计将于2025年获得NDA批准并在中国商业化推出。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"异动解读 | GLP-1赛道新星派格生物医药-B盘中大涨5.36%，投资者看好其商业化前景","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["02565"],"gpt_icon":1},{"id":"2538418150","title":"21健讯Daily｜小儿感冒宁颗粒和蒲公英颗粒转为非处方药；派格生物港交所上市；漱玉平民股东拟减持","url":"https://stock-news.laohu8.com/highlight/detail?id=2538418150","media":"21财经网","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538418150?lang=zh_cn&edition=fundamental","pubTime":"2025-05-28 07:45","pubTimestamp":1748389549,"startTime":"0","endTime":"0","summary":"政策动向小儿感冒宁颗粒和蒲公英颗粒转换为非处方药5月27日，国家药监局公告称，根据《处方药与非处方药分类管理办法（试行）》规定，经国家药监局组织论证和审核，小儿感冒宁颗粒和蒲公英颗粒由处方药转换为非处方药。行业大事派格生物港交所上市5月27日，派格生物正式登陆港股，在联交所上市。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202505280745559504d5c1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202505280745559504d5c1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02565"],"gpt_icon":1},{"id":"2538415287","title":"核药龙头与GLP-1新锐齐赴港，科五标准重启，Biotech IPO春天来了？","url":"https://stock-news.laohu8.com/highlight/detail?id=2538415287","media":"药渡","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538415287?lang=zh_cn&edition=fundamental","pubTime":"2025-05-28 07:32","pubTimestamp":1748388743,"startTime":"0","endTime":"0","summary":"5月26日，核药龙头向港交所递交上市申请:今日，GLP-1新锐正式在港交所挂牌上市。02GLP-1赛道派格生物成功港股IPO5月27日，聚焦代谢性疾病治疗的派格生物在港股成功上市。自今年3月中国证监会提出“增强制度包容性”以来，科创板“第五套标准”迎来实质性松动。在此背景下，像先通医药、派格生物这样具备“可预期商业化+高技术壁垒”的Biotech企业正迎来新一轮IPO窗口期。科创板“第五套标准”落地的典型案例越多，越能带动上下游Biotech募资热情。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250528084638a48efc5e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250528084638a48efc5e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02565","BK1515","BK1574","09939","BK1161"],"gpt_icon":1},{"id":"2538049434","title":"产业投资丨中新资本已投企业派格生物（2565.HK）成功登陆港交所","url":"https://stock-news.laohu8.com/highlight/detail?id=2538049434","media":"中新集团","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538049434?lang=zh_cn&edition=fundamental","pubTime":"2025-05-27 21:28","pubTimestamp":1748352538,"startTime":"0","endTime":"0","summary":"5月27日中新集团旗下中新资本已投企业派格生物在港交所上市派格生物此次全球发售1928.35万股，募集资金约3.01亿港元，将用于PB-119商业化及适应症扩展、PB-718的进一步开发、其他管线候选产品研发、业务开发及营运资金等。未来，中新集团将持续坚持以产为核聚焦新质生产力立足园区主导产业不断强化产业投资能力以投带招、以招促投、投招联动促进产业导入、加速产业发展助力国家科技创新和产业升级","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250528042341a48ec6d9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250528042341a48ec6d9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02565"],"gpt_icon":1},{"id":"2538430789","title":"今天，杭州派格生物IPO了","url":"https://stock-news.laohu8.com/highlight/detail?id=2538430789","media":"投资界","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538430789?lang=zh_cn&edition=fundamental","pubTime":"2025-05-27 14:52","pubTimestamp":1748328720,"startTime":"0","endTime":"0","summary":"不过，截至目前，派格生物没有产品获批进行商业销售，也因此公司没有盈利且录得经营亏损。于2023年、2024年，派格生物其他净收入分别为1464万元、701万元；年内亏损分别为2.79亿元、2.83亿元。2022年12月，派格生物再度启动A股IPO，无功而返。如今，年逾六旬的徐敏迎来了人生第一个IPO。当时，派格生物与天士力签订了协议，以推动相关产品的商业化。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250527154551a48dfc31&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250527154551a48dfc31&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0052756011.USD","LU0264606111.USD","80992","LU0791591158.USD","HK0000320264.USD","LU1046422090.SGD","IE0032431581.USD","BK1193","LU0791590937.USD","LNVGY","LU2242644610.SGD","IE0034224299.USD","HK0000306701.USD","LU0128525689.USD","LU0310800965.SGD","LU1366334578.USD","IE00B0JY6N72.USD","02565","LU0049112450.USD","LU1267930227.SGD","HK0000306685.HKD","BK1526","00992","BK1607","LU0572940350.SGD","LU1235295612.USD","HK0000320223.HKD","LU0572939691.SGD","LU1366334651.USD"],"gpt_icon":1},{"id":"2538890431","title":"市值超48亿！联想云锋投的“减肥药”IPO了","url":"https://stock-news.laohu8.com/highlight/detail?id=2538890431","media":"猎云网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538890431?lang=zh_cn&edition=fundamental","pubTime":"2025-05-27 13:57","pubTimestamp":1748325427,"startTime":"0","endTime":"0","summary":"公司于2021年8月向科创板提交过IPO申请，于2022年4月撤回申请；进入2024年，尚未盈利的派格生物转战港股，寻求上市机会；今年4月，派格生物医药通过港交所聆讯。在财务方面，派格生物目前尚未获得任何可用于商业销售的产品，也没有从产品销售中获得任何收入。2023年和2024年，公司的税前亏损分别为2.79亿元和2.83亿元。2023年6月，派格生物完成IPO前最后一轮融资，投后估值为40亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202505271357459503eb5c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202505271357459503eb5c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0264606111.USD","LU0791590937.USD","02565","80992","IE00B0JY6N72.USD","HK0000320223.HKD","00992","LNVGY","LU1046422090.SGD","HK0000306701.USD","BK1526","LU2242644610.SGD","LU1235295612.USD","BK1193","LU0049112450.USD","LU0128525689.USD","BK1607","HK0000306685.HKD","LU0572940350.SGD","LU0791591158.USD","IE0034224299.USD","HK0000320264.USD","IE0032431581.USD","LU1366334578.USD","LU0572939691.SGD","LU0052756011.USD","LU0310800965.SGD","LU1366334651.USD","LU1267930227.SGD"],"gpt_icon":1},{"id":"1108998276","title":"港股异动丨派格生物医药-B上市首日破发，一度大跌26%","url":"https://stock-news.laohu8.com/highlight/detail?id=1108998276","media":"老虎资讯综合","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1108998276?lang=zh_cn&edition=fundamental","pubTime":"2025-05-27 10:48","pubTimestamp":1748314113,"startTime":"0","endTime":"0","summary":"派格生物是一家生物技术公司。","market":"hk","thumbnail":"https://static.tigerbbs.com/9337c776035ecf1422fc5292f1ebe542","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/9337c776035ecf1422fc5292f1ebe542"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02565"],"gpt_icon":0},{"id":"2538438148","title":"中银国际助力派格生物成功在香港联交所上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2538438148","media":"中银国际","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538438148?lang=zh_cn&edition=fundamental","pubTime":"2025-05-27 10:31","pubTimestamp":1748313069,"startTime":"0","endTime":"0","summary":"2025年5月27日，中银国际作为联席全球协调人、联席账簿管理人及联席牵头经办人协助派格生物在香港联合交易所成功上市。派格生物是一家专注于以肽和小分子药物治疗慢性病的生物技术公司。上市概况派格生物此次全球发行19,283.500股H股，发行价格定于每股15.6港元，总募集金额约3亿港币。此次派格生物在香港公开发售项下，公司合共接获约5万份有效申请，认购股数约为香港公开发售初步可供认购香港发售股份总数193万股的744倍。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250527111438a6ee423f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250527111438a6ee423f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02565"],"gpt_icon":1},{"id":"2538480310","title":"港交所又迎来一家药企上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2538480310","media":"动脉网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538480310?lang=zh_cn&edition=fundamental","pubTime":"2025-05-27 10:23","pubTimestamp":1748312580,"startTime":"0","endTime":"0","summary":"派格生物在港交所上市，募资约2.32亿港元，用于创新药研发等项目，核心产品PB-119预计2025年商业化。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025052710295797669d3c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025052710295797669d3c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1521","LU1366334651.USD","LU1504937902.USD","LU0348814723.USD","IE00BZ08YS42.EUR","LU0417516902.SGD","LU0831103253.SGD","BK1161","LU0577902298.EUR","SG9999001093.SGD","LU0605514214.HKD","LU0048597586.USD","LU0417516738.SGD","LU1282649810.SGD","IE00B3T34201.USD","LU0791590937.USD","LU1366334578.USD","LU0607220059.USD","LU0067412154.USD","SG9999004220.SGD","06978","HEXmain","LU1044876610.USD","BK1589","02565","LU0348816934.USD","LU1981816686.USD","LU1993786604.SGD","LU2449936058.SGD","LU0630378692.HKD","80388","LU0594300419.USD","LU0979878070.USD","LU0197773673.USD","LU0211977185.USD","LU0196878994.USD","LU0577902454.USD","LU0572944931.SGD","LU0797268264.HKD","LU1807302812.USD","LU2039709279.SGD","LU1226287529.USD","LU0516423091.SGD","LU1282649067.USD","HKXCY","LU0516423174.USD","00388","LU0164880469.USD","LU0516422952.EUR","LU1328277881.USD","LU0048580855.USD"],"gpt_icon":0},{"id":"2538482955","title":"《股市简讯》中国“减肥药概念股”派格生物医药香港首日挂牌盘初插水近三成","url":"https://stock-news.laohu8.com/highlight/detail?id=2538482955","media":"路透中文","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538482955?lang=zh_cn&edition=fundamental","pubTime":"2025-05-27 09:50","pubTimestamp":1748310643,"startTime":"0","endTime":"0","summary":"《股市简讯》中国“减肥药概念股”派格生物医药香港首日挂牌盘初插水近三成* 中国生物技术公司--派格生物医药2565.HK周二香港首日挂牌开低17%后，盘初扩大跌幅至28%，低探11.22港元。* 该公司专注于代谢紊乱领域，其自主开发、接近商业化阶段的核心产品PB-119主要用于2型糖尿病及肥胖症一线治疗。* 是次在香港上市集资3亿港元，招股价为每股15.6港元，公开发售及国际配售分别获744倍及1.1倍认购。（完）更多股市简讯请点选CN-CMN-HOT (记者 雷美珍；审校 田镧沁) ((alison.lui@thomsonreuters.com; +852 3462 7749;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"9def1a2fcaf9e5fd93e233e38a747185","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250527:nL3T3RZ041:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02565"],"gpt_icon":0},{"id":"2538435278","title":"中泰国际助力减重疗法概念股－“派格生物医药”（2565.HK）成功上市！","url":"https://stock-news.laohu8.com/highlight/detail?id=2538435278","media":"中泰金融国际","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538435278?lang=zh_cn&edition=fundamental","pubTime":"2025-05-27 09:48","pubTimestamp":1748310532,"startTime":"0","endTime":"0","summary":"中泰国际作为联席账簿管理人及联席牵头经办人的项目，减重疗法概念股 –派格生物医药( 杭州) 股份有限公司于2025年5月27日成功上市。派格生物医药本次全球发行约1928.35万股H股，定价为每股H股15.60港元，集资总额约3.01亿港元。派格生物医药( 杭州) 股份有限公司派格生物医药，成立于2008年，作为一家专注于自主研究及开发慢性病创新疗法的生物技术公司，重点关注代谢紊乱领域。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250527122532a48dc544&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250527122532a48dc544&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02565"],"gpt_icon":1},{"id":"1125211878","title":"异动解读 | 派格生物医药-B上市首日暴跌15%，开盘即破发","url":"https://stock-news.laohu8.com/highlight/detail?id=1125211878","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1125211878?lang=zh_cn&edition=fundamental","pubTime":"2025-05-27 09:32","pubTimestamp":1748309561,"startTime":"0","endTime":"0","summary":"5月27日，新上市的派格生物医药-B股价表现不佳，盘中大跌15%，引发市场关注。该公司今日在港交所挂牌上市，但开盘即告破发，开盘价为13港元，较发行价15.6港元下跌16.67%。尽管公开发售反应热烈，但派格生物医药-B上市首日的股价表现却令投资者失望。作为一家专注于慢性病创新疗法研发的生物科技公司，派格生物医药-B的核心产品PB-119虽已接近商业化阶段，但投资者可能需要更多时间来评估公司的长期发展前景。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"9def1a2fcaf9e5fd93e233e38a747185","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["02565"],"gpt_icon":0},{"id":"1116268702","title":"异动解读 | 派格生物医药-B上市首日遭遇破发，盘中大跌15%","url":"https://stock-news.laohu8.com/highlight/detail?id=1116268702","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1116268702?lang=zh_cn&edition=fundamental","pubTime":"2025-05-27 09:32","pubTimestamp":1748309550,"startTime":"0","endTime":"0","summary":"港股新上市公司派格生物医药-B今日迎来挂牌首日，却遭遇\"开门黑\"。该股在交易时段内大跌15%，引发市场关注。派格生物医药-B此前公布的招股结果显示，公司IPO定价为每股15.6港元，公开发售部分获得743.78倍超额认购，一手中签率仅为8%。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"9def1a2fcaf9e5fd93e233e38a747185","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["02565"],"gpt_icon":0},{"id":"2538348603","title":"9轮融资、众多头部机构加持，减肥药明星企业今日IPO","url":"https://stock-news.laohu8.com/highlight/detail?id=2538348603","media":"动脉网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538348603?lang=zh_cn&edition=fundamental","pubTime":"2025-05-27 08:09","pubTimestamp":1748304549,"startTime":"0","endTime":"0","summary":"在火热的T2DM及减肥赛道，派格生物是一级市场的明星项目。招股书显示，在IPO之前，派格生物于2008年至2023年之间先后获得9轮融资，投资方包括元生创投、泰格医药、盈科资本、前海、君联资本等一众知名机构与企业。初步研究结果表明，PB-718可减少肝脏中的脂质积累，从而防止肝脏炎症和随后出现的肝纤维化。截至2025年2月，国内已有15款用于治疗T2DM的GLP-1药物，以及6款用于肥胖症的药物。此外，也有GLP-1减重药物将医美机构纳入营销网络。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250527081209a6ee13e3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250527081209a6ee13e3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["03347","BK1141","02565","BK1583","BK1576"],"gpt_icon":1},{"id":"1146090593","title":"新股定价 | 派格生物医药每股定价15.6港元，公开发售获743.78倍认购，一手中签率8%","url":"https://stock-news.laohu8.com/highlight/detail?id=1146090593","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1146090593?lang=zh_cn&edition=fundamental","pubTime":"2025-05-27 08:05","pubTimestamp":1748304305,"startTime":"0","endTime":"0","summary":" $派格生物医药-B(02565)$ 公布招股结果，香港公开发售接获743.78倍认购，一手(500股)中签率8%，认购10万股始获稳派一手。按回补机制，公开发售股份已增至964.2万股，占发售总数50%。国际配售录得1.13倍认购。发售价15.6港元，集资净额2.32亿港元元。股份预期周二(27日)上市。生物技术公司派格生物医药本次拟全球发售1,928.35万股，香港公开发售原占10%。基石投资者益泽康瑞旗下益泽康瑞医药(香港)获分配958.45万股，占发售後H股股本3.43%。","market":"hk","thumbnail":"https://community-static.tradeup.com/news/8fe389b09b53c9beb073f83ce44ec0c0","type":0,"news_type":0,"thumbnails":["https://community-static.tradeup.com/news/8fe389b09b53c9beb073f83ce44ec0c0"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"9def1a2fcaf9e5fd93e233e38a747185","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":"派格生物医药每股定价15.6港元，公开发售超购742倍，一手中签率8%","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02565"],"gpt_icon":0}],"pageSize":20,"totalPage":5,"pageCount":4,"totalSize":83,"code":"91000000","status":"200"}]}}